PharmaFocus Today – Page 6 – media

Eli Lilly invests $3 billion in China

Recently, Eli Lilly announced plans to invest a total of $ 3 billion over the next ten years to fully expand its supply chain capacity in China . According to the plan, the $3 billion investment will adopt a dual-track model of ” internal expansion + external cooperation “: on the one hand, it will leverage the technological and talent advantages of the Suzhou factory to strengthen the synergistic production capacity of incretin injection; on the other hand, it will add oral solid dosage form production capacity in Beijing and cooperate with multiple local production partners to release incremental production capacity. As a key move in this round of investment, Eli Lilly also announced a strategic partnership with Kanglong Chemical , a leading domestic CDMO company , on the same day. The initial investment of $200 million will support Kanglong’s technological capabilities, with plans to gradually expand the scale as ...
- Source: drugdu
- 74
- March 17, 2026
Medtronic invests $550 million in neurointerventional surgery.

According to recent foreign media reports, global medical device giant Medtronic announced that it will acquire Scientia Vascular for $550 million to strengthen its stroke treatment portfolio. Image source: Fierce Biotech Scientia Vascular is a company specializing in the manufacture of specialized guidewires, microcatheters, and access products for reaching complex blood clots deep in the brain. According to data from PharmNet Medical Devices, the company has already launched 16 products in the United States. In 2021, Scientia completed a $50 million funding round, which the company reportedly used to accelerate sales, marketing, and new product development in its core neurovascular stroke market, as well as peripheral vascular and interventional oncology-related markets. Scientia’s process involves etching slots into a solid nickel-titanium alloy tube to form a closed loop and interconnected beams—allowing the guidewire to effectively transmit torque while meandering through the brain’s small, winding blood vessels. The company states that this ...
- Source: drugdu
- 72
- March 17, 2026
Roche’s blockbuster new drug receives approval for a new indication, becoming the world’s first to do so.

Diffuse large B-cell lymphoma ( DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting for 31%–34% of NHL cases globally and 45.8% in China. The incidence rate increases with age. Even after first-line treatment, 30%–40% of DLBCL patients face relapse or refractory outcomes, resulting in a poor prognosis and challenging survival.On March 13, 2026, according to the latest announcement on the official website of the National Medical Products Administration (NMPA) of China , Roche (China) Investment Co., Ltd. ‘s application for a new indication for injectable veportuzumab has been approved for marketing in China . According to Roche’s press release, the indication is: this product in combination with rituximab , gemcitabine, and oxaliplatin (Pola-R-GemOx) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not suitable for hematopoietic stem cell transplantation. Public information shows that vedotin (Urithema®, Polivy®) is an antibody-drug conjugate (ADC) targeting ...
- Source: drugdu
- 87
- March 17, 2026
Lunan Pharmaceutical’s carfilzomib API receives dual approval from China and the US for market launch.

Recently, Shandong New Era Pharmaceutical Co., Ltd., a subsidiary of Lunan Pharmaceutical Group, received a marketing authorization notice for carfilzomib issued by the National Medical Products Administration . This approval further enriches the company’s anti-tumor active pharmaceutical ingredient (API) product line. The product, manufactured using the same production line and process, has also been submitted for US approval, providing a better option for domestic and international pharmaceutical formulation customers. Carfilzomib, as a second-generation proteasome inhibitor, exerts significant anti-proliferative and pro-apoptotic effects on tumor cells by irreversibly binding to the 20S proteasome active site. Its high selectivity results in a lower risk of neurotoxicity, and it is well tolerated by patients. Clinical data confirm that it has a reliable safety advantage in the treatment of multiple myeloma and is the preferred clinical option. Established in 2017, the International Drug R&D Center adheres to an international strategy of “based in China, radiating ...
- Source: drugdu
- 51
- March 17, 2026
Unknown Risks Associated with Tirzepatide + Vitamin B12

On March 12, 2026, Eli Lilly and Company issued an open letter to the public, warning of potential safety risks associated with compounded medications that mix tirzepatide with vitamin B12. Lilly stated that its testing revealed a chemical reaction between tirzepatide and B12 in compounded formulations, producing significant levels of unknown impurities. The short term and long term effects of these impurities on the human body remain completely unknown. This warning has once again drawn public attention to the gray area of compounded drug formulations. Unknown Impurities Detected Safety Profile Completely Unknown In its open letter, Eli Lilly disclosed that it had tested commercially available compounded products combining tirzepatide with B12 (including methylcobalamin, hydroxocobalamin, or cyanocobalamin) and found them to contain substantial levels of unknown impurities. These impurities are products of a chemical reaction between tirzepatide and B12. Lilly emphasized that no research data exist regarding the pharmacological properties ...
- Source: drugdu
- 84
- March 16, 2026
A New Generation of 10-Billion-Level Anticoagulant Drug Is Coming

Anticoagulants occupy a unique niche on the global bestselling drugs ranking. Unaffected by sudden pandemics or short-lived market trends, they have long secured a core position in the global pharmaceutical market driven by rigid clinical demand. In 2025, apixaban ranked sixth globally with $14.4 billion in worldwide sales, earning its title as the undisputed “King of Anticoagulants”. This sales figure not only surpassed blockbuster oncology drugs such as Opdivo and daratumumab, but also exceeded popular chronic disease medications like dapagliflozin. Beneath this prosperity, however, patents are expiring, and the billion-dollar era of the “xaban” class is drawing to a close. Yet the anticoagulant sector will not halt its progress: a new generation of blockbuster drugs is on the horizon. / 01 / An Unmatched Commercial Logic The enormous size of the anticoagulant market is hardly surprising. As the name suggests, antithrombotic drugs inhibit thrombus formation, promote thrombolysis, or prevent ...
- Source: drugdu
- 73
- March 16, 2026
Hua Medicine’s Innovative Drug Approved for Launch in Hong Kong via “Direct Access” Pathway!

Recently, Dorzagliatin, an innovative type 2 diabetes drug developed by Hua Medicine, has been approved for marketing by the Office of Pharmaceutical Products, Department of Health, Hong Kong Special Administrative Region. It has become the first general drug (a widely used medicine for common diseases) approved under Hong Kong’s “1+” Fast Track Approval Mechanism for new drugs. In 2023, the Shanghai-based enterprise highlighted through this newspaper the difficulties faced by domestic innovative drugs in seeking market approval in Hong Kong. Today, its wish has been fulfilled, as the innovative drug has been approved via the “direct access” route in Hong Kong. Holding both mainland and Hong Kong drug registration certificates, the company plans to expand to Southeast Asia, opening up broad overseas markets for domestic innovative drugs. For a long time, Hong Kong implemented the “2+” Approval Mechanism, which required new drugs to be first launched in two “listed countries” ...
- Source: drugdu
- 61
- March 16, 2026
Huige Portfolio | Baitewei Medical Completes Nearly 100 Million Yuan Series B Financing to Accelerate Innovative Product Layout in Peripheral Vascular Intervention and Heart Failure Fields

Recently, Shenzhen Baitewei Medical Technology Co., Ltd. (“Baitewei Medical”) announced the completion of a nearly 100 million yuan Series B financing round. The round was led by Tasly Capital, with Qinzhi Capital as a co-investor, and Vision Capital acted as the exclusive financial advisor. The proceeds will mainly be used for new product R&D, production base construction and market expansion, accelerating the company’s layout of innovative products in peripheral vascular intervention and heart failure. Building a peripheral intervention product matrix, achieving domestic breakthroughs in multiple devices In the field of peripheral vascular intervention, Baitewei has established a full product matrix covering “thromboreduction + thrombectomy + access”, with multiple technologies at a leading domestic level. Several devices have achieved domestic breakthroughs and successfully obtained market approval. Meanwhile, a number of additional innovative products are in the clinical application and registration stage, forming a full-cycle and sustainable product R&D and commercialization ...
- Source: drugdu
- 58
- March 16, 2026
Fangda Pharma helps Jiminke’s Class 1 innovative drug, Jilemei®, obtain market approval.

Recently, Jilemei® (soximerexyl sulfate tablets), a Class 1 innovative drug supported by Fangda Pharmaceutical (Suzhou) Co., Ltd. in the clinical stage, has been granted priority review and approval by the National Medical Products Administration and conditionally approved for marketing . Developed by Zhejiang Hangyu Pharmaceutical, a subsidiary of Jiming Kexin , this drug is intended to treat adult patients with advanced non-small cell lung cancer ( NSCLC ) with murine sarcoma virus oncogene ( KRAS ) G12C mutation who have received at least one systemic therapy , providing a new treatment option for this lung cancer subtype with a well-defined molecular target. As a partner, Fangda’s team completed the production , quality release, and stability studies of Phase I and Phase II clinical samples , and provided integrated services such as clinical double-blind labeling , sample storage management , clinical drug delivery, and international transportation . With its efficient, professional, ...
- Source: drugdu
- 81
- March 13, 2026
Dexamethasone API Marketing Application Approved

March 13th – Cyto BiotechThe announcement stated that the company’s controlling subsidiary, Shandong Srui Pharmaceutical Co., Ltd., received a certificate from the National Medical Products Administration for dexamethasone, a chemical raw material.”Notification of Approval for Drug Marketing Application”. Dexamethasone is a long-acting glucocorticoid with anti-inflammatory, anti-allergic, and immunosuppressive effects. It is mainly used for allergic and autoimmune inflammatory diseases, such as connective tissue diseases, severe bronchial asthma, dermatitis, ulcerative colitis, acute leukemia, and malignant lymphoma. https://finance.eastmoney.com/a/202603133671477849.html
- Source: drugdu
- 68
- March 13, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.